Navigation Links
Blood protein may hold key to stopping tumor growth in cancer patients
Date:3/31/2009

WINSTON-SALEM, N.C. A recent discovery by researchers at Wake Forest University School of Medicine could clear the way for a new drug that inhibits tumor growth in cancer patients and could potentially help in the healing of wounds.

The discovery stems from a study, recently published in the Proceedings of the National Academy of Sciences of the United States of America, in which researchers looked at angiogenesis the body's formation of new blood vessels from existing blood vessels and how some blood proteins are involved in that process and affect blood vessel growth.

Researchers found that a protein called ferritin binds to and cripples the ability of another blood protein, called HKa, to shut down blood vessel growth. Because new blood vessels supply a steady stream of nutrients and oxygen that are essential for tumor growth, researchers found that the binding of the two proteins actually assists in new blood vessel formation by removing HKa's influence and therefore promotes tumor growth.

The finding led researchers to the hypothesis that if they can somehow prevent the binding of ferritin and HKa, it will allow HKa to prevent new blood vessel growth and therefore block the growth of tumors.

The finding also has possible implications for wound care. In order to heal, wounds need blood vessel growth. It is therefore possible that by increasing the binding of ferritin to HKa, one could increase the rate at which a serious wound heals.

"It's been known for a long time that levels of ferritin are increased in people with tumors, but it's never been understood why that happens," said Suzy V. Torti, Ph.D., the study's lead investigator, an associate professor of biochemistry and an expert in iron biology at the School of Medicine. "Ferritin appears to play an important role in blood vessel formation. Further, the interaction between ferritin and HKa may represent a new area of interest for possible drug development."

For the study, researchers injected mice with prostate cancer cells to determine how ferritin and HKa affected the formation of new blood vessels.

The mice injected with the cancer cells grew tumors. But when researchers mixed HKa with the tumor cells, the HKa inhibited blood vessel formation. When researchers added ferritin to the mixture of HKa and cancer cells, however, the ferritin restored blood vessel formation, allowing the tumors to grow again.

"Blood vessels can either be helpful, for example in wound healing, or they can be harmful, for example by favoring tumor growth," Torti said. "Our new finding is that the interaction between ferritin and HKa can influence blood vessel formation. This finding could serve as the basis for strategies to either inhibit or stimulate blood vessels. This opens up a new realm of potential ways to treat tumors or other conditions that depend on new blood vessel formation."

The research team, supported by a National Institutes of Health grant, has begun work to develop an anti-tumor drug based on their findings.

Lan G. Coffman, Ph.D., Derek Parsonage, Ph.D., Ralph D'Agostino Jr., Ph.D., and Frank M. Torti, M.D., M.P.H, all of the Wake Forest University School of Medicine, also collaborated on the study.


'/>"/>

Contact: Jessica Guenzel
jguenzel@wfubmc.edu
336-716-3487
Wake Forest University Baptist Medical Center
Source:Eurekalert

Related medicine news :

1. Effort Could Lead to Blood Tests for Heart Problems
2. Blood test for brain injuries gains momentum
3. After heart attack, bone marrow stem cells increase blood flow within heart
4. Statin Might Help Fight Blood Clots in Veins
5. Video: CRESTOR(R) Reduced Risk of Blood Clots in the Veins
6. LegalView Informs Baxter Heparin Patients of New Testing Standards for Blood Thinner Following Deaths From Previous Contamination
7. Kidney Ailments May Rise Along With Blood Pressure
8. Cord Blood America Applauds Congressional Effort Supporting Cord Blood Storage
9. Cord Blood Registry Supports Family Cord Blood Banking Act
10. Researchers decipher blood stem cell attachment, communication
11. Cord Blood America Announces Results of Shareholder Special Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... (PRWEB) , ... April 26, ... ... which provides an agile ecosystem and domain expertise for sponsors and CROs ... randomization and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... ... April 25, 2017 , ... Coalition ... for Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics ... HOPE clinical trial in Duchenne announced today. , Coalition Duchenne funded studies ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting new ... in Lutz, FL. With the help of this highly-effective, yet convenient system, patients ... complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara ...
(Date:4/25/2017)... ... 2017 , ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace ... help but be heartened by the industry’s current surge. But another thing that unifies ... smell.” At last they can simply, safely and effectively end their aroma anguish ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... products, is introducing Flexadin UCII, part of the EQUISTRO line, at this week’s ... health in horses at the immunologic level. , The scientifically-developed Flexadin UCII supports ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... , April 24, 2017 Solentim, ... today announced the addition of a major new ... In-situ Plate Seeding,). The VIPS has been developed ... 384 well microplates as part of the process ... offers a simple and more reliable solution when ...
(Date:4/20/2017)... PLANO, Texas , April 20, 2017  Vivify ... via mobile devices, has been awarded a very significant ... care via EMRs to continual care via digital health. ... of key intellectual property and further secures Vivify,s position ... Vivify, launched in 2009, was the first company to ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
Breaking Medicine Technology: